Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.

The group was recently asked to provide input on a new set of recommendations for image-guided biopsies of suspicious breast lesions—offering providers clarity on key clinical scenarios.

AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.

The Volt Pulsed Field Ablation System from Abbott has been approved by the FDA. The technology, which gained CE mark approval in March, features a one-of-a-kind catheter design and allows patients to be treated under conscious sedation.

The key agency released a request for information on Dec. 19, asking for broad input on how it can accelerate the adoption of AI in clinical care. 

Ferumoxytol is used primarily in medications that treat anemia, but the FDA recently cleared it for deployment in brain imaging as well.

The U.S. Department of Justice has formally accused Done Global of unlawfully distributing ADHD medications without medical need, using a subscription program and targeted advertising to find patients searching for drugs. The company is also accused of filing false medical claims to Medicare, Medicaid and commercial insurance. Done's founder and CEO was convicted last month on related charges and awaits sentencing. 

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.